编辑丨王多鱼 排版丨水成文 在大量的 1 型糖尿病 患者中，尽管进行了胰岛素治疗，但血糖目标仍可能无法达成，而由胰岛素过量导致的反复严重低血糖问题可能会造成不可逆的神经损伤甚 至死亡。 异体和终末分化自体干细胞来源的胰岛，已在临床试验中提供了令人信服的证据，表明此类疗法能够恢复 1 型糖尿病和 2 型糖尿病患者的持久正常血糖胰岛功 能。然而，迄今为止，所有 接受自体来源的再生胰岛移植的 1 型糖尿病患者，此前都已进行了肾脏 或肝脏移植，它们已需要全剂量免疫抑制维持。因此，1 型糖 尿病 患者接受自体来源的再生胰岛移植是否需要长期使用免疫抑制剂以及所需免疫抑制的类型/剂量，仍亟待回答。 2026 年 2 月 26 日， 海军军医大学上海长征医院 殷浩 教授、中国科学院 分子细胞科学卓越创新中心 程新 研究员 、 加拿大 阿尔伯塔大学 James Shapiro 教 授、上海交通大学医学院附属仁济医院 张明 教授及海军军医大学上海长征医院 李圣贤 教授作为共同通讯作者 （ 石勇铨 、 冯亦凡 、 李拓 、 凌清 、 吴佳颖 、 付天龙 、 聂螣騛 、 郭猛 为论文共同第一作者 ） ，在《柳叶刀》子刊 The La ...

中证报中证网讯（记者 宋维东）记者2月27日从通化东宝（600867）获悉，公司日前与港股上市公司四 环医药控股子公司惠升生物签署《商业化合作协议》。双方携手布局糖尿病治疗领域，实现资源互补、 协同发展。本次合作，将进一步丰富通化东宝在内分泌代谢领域的产品矩阵，持续巩固其在糖尿病治疗 领域的综合竞争力，为长期、可持续发展增添动能；惠升生物也有望借此次合作快速提升相关产品的市 场渗透率，进一步释放产品市场价值。双方将以此次合作为契机，共同推动优质国产胰岛素产品惠及更 广泛患者群体，实现互利共赢与高质量发展。 作为国产胰岛素龙头企业，通化东宝深耕糖尿病用药领域多年，拥有深厚的市场基础、成熟的商业化体 系及良好的品牌影响力，产品市场占有率长期位居国内同类产品前列。公司构建的覆盖全国的成熟商业 化网络，深入各级医疗机构与基层市场，具备高效推进产品准入、学术推广及终端放量的综合能力，能 为产品实现快速、广泛市场覆盖提供坚实支撑。此次合作，立足于通化东宝与惠升生物在各自领域的深 厚积淀，双方均对合作前景高度认可。未来，通化东宝将发挥内分泌代谢领域的商业化优势，加速惠优 加、惠优达市场推广与临床应用；惠升生物将持续增强研发 ...

Summary of Biomea Fusion FY Conference Call Company Overview - **Company**: Biomea Fusion (NasdaqGS: BMEA) - **Key Products**: - Icovamenib: An oral small molecule for diabetes - BMF-650: A GLP-1 receptor agonist for weight loss Core Insights and Arguments Icovamenib Development - **Clinical Trials**: - Currently moving into two clinical trials targeting insulin-deficient type 2 diabetes and patients inadequately controlled on GLP-1 therapy [3][11] - **Market Need**: - Diabetes is a significant health issue, with approximately 38 million people in the U.S. affected, and 80% of diabetes patients die from related complications [4][49] - **Efficacy**: - Icovamenib showed a significant reduction in A1C levels over time, with effects lasting up to 9 months post-treatment [5][10] - Mechanism involves the inhibition of menin, which enhances insulin production by increasing beta cell proliferation [6][7] - **Patient Population**: - Focus on patients with A1C levels between 7.5 and 10.5, BMI less than 32, and those who have failed 1-3 prior diabetes medications [25][26] BMF-650 Development - **Clinical Trials**: - Currently in Phase 1 studies, aiming for a favorable pharmacokinetic profile and consistent weight loss response [13][15] - **Weight Loss Efficacy**: - Initial studies in monkeys showed a weight reduction of approximately 12% to 15% over 28 days [14] - **Market Positioning**: - Positioned to address the needs of patients who are overweight or obese and require effective weight management solutions [95][104] Additional Important Points - **Regulatory Strategy**: - The current studies are not registrational but are designed to gather data that could support future Phase 3 trials [75][76] - **Commercial Focus**: - Targeting patients who are uncontrolled on standard therapies, particularly those failing GLP-1 treatments, to prevent progression to insulin dependency [44][49][92] - **Market Size**: - The diabetes market is substantial, with over 10 million insulin-dependent patients in the U.S. alone [44][49] - **Long-term Goals**: - Aim to provide a non-chronic treatment option that can restore beta cell function and reduce the healthcare burden associated with diabetes [61][62] Conclusion - Biomea Fusion is advancing its innovative diabetes treatments, Icovamenib and BMF-650, with a clear focus on addressing unmet needs in the diabetes market. The company is strategically positioning itself to capture a significant share of the market by targeting specific patient populations and demonstrating the efficacy of its therapies through ongoing clinical trials.

Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 4% in the afternoon, currently up 3.85% at HKD 13.76, with a trading volume of HKD 12.1855 million. The company announced the completion of the first patient dosing in a Phase II clinical trial in the U.S. for its oral GLP-1 receptor agonist ASC30, aimed at treating type 2 diabetes, with plans to recruit approximately 100 patients across multiple centers in the U.S. The primary data from this 13-week study is expected to be released in Q3 2026 [1]. Group 1 - Gilead Sciences has initiated a Phase II clinical trial for ASC30, targeting type 2 diabetes treatment [1]. - The trial will involve around 100 patients and is set to take place in multiple centers across the U.S. [1]. - The company plans to announce the primary data from the trial in Q3 2026 [1]. Group 2 - The CEO of Gilead Sciences, Dr. Wu Jinzi, emphasized the strategic expansion into the diabetes treatment market with ASC30 [1]. - The company aims to showcase ASC30 as a potential best-in-class oral treatment option, administered once daily [1]. - The upcoming trial results are anticipated to provide significant insights into the efficacy of ASC30 for diabetes patients [1].

Core Viewpoint - The announcement of the completion of the first patient dosing in the Phase II clinical trial of ASC30 for type 2 diabetes treatment has positively impacted the stock price of the company, leading to a rise of over 4% [1] Company Developments - The company, Songlei Pharmaceutical, has initiated a Phase II clinical trial in the United States for its oral small molecule GLP-1 receptor agonist ASC30, targeting approximately 100 type 2 diabetes patients across multiple centers [1] - The primary data from this 13-week Phase II study is expected to be released in the third quarter of 2026 [1] - The founder and CEO, Dr. Wu Jinzi, emphasized the strategic importance of expanding ASC30's clinical development into the large diabetes treatment market, highlighting its potential as a best-in-class oral treatment option [1]

Core Findings - The research identified the olfactory receptor Or5v1/Olfr110 as a high-affinity receptor for the oxylipin 12(S)-HEPE, which promotes hepatic fatty acid oxidation and improves glucose homeostasis, thereby reducing obesity [3][5][7] - The activation level of the Or5v1/Olfr110-Gs signaling pathway is lower in obese patients compared to normal individuals, indicating a correlation between lower receptor activity and higher body mass index (BMI) [5][7] - The synthetic agonist HOR1-C59, developed based on structural analysis, shows beneficial effects on glucose homeostasis, highlighting the clinical application value of targeting olfactory receptors with small molecule compounds in disease treatment [6][7] Methodology - The research utilized a novel technique called "anonymous receptor identification by reverse-G-protein pull-down" (ARIG) to identify the orphan receptor Or5v1/Olfr110 as a receptor for oxylipids [5][7] - The study demonstrated that systemic or liver-specific knockout of Or5v1/Olfr110 impairs glucose homeostasis, even in the presence of 12(S)-HEPE stimulation [5][6] Implications - The findings suggest that targeting the olfactory receptor Or5v1/Olfr110 could provide new therapeutic strategies for treating obesity, diabetes, and fatty liver diseases [3][6][7] - The research emphasizes the importance of olfactory receptors in metabolic processes and their potential as drug targets [6][7]

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its SGLT-2 inhibitor, Ologliptin capsules, which are intended for improving blood glucose control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also showed additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes is now the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in diabetes treatment, including five insulin products that have been approved and are consistent in effectiveness, safety, and quality with original formulations [2] - The new product approval will enhance the company's diabetes product portfolio, and the company plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its innovative drug, Ologliptin capsules, which are designed to improve blood sugar control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also offers additional metabolic benefits such as weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood sugar, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in the diabetes treatment field, including five insulin products that have been approved and are consistent in efficacy, safety, and quality with original formulations [2] - The approval of the new product will enhance the company's diabetes product portfolio, and it plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - Dongyangguang Pharmaceutical (06887.HK) announced that its self-developed SGLT-2 inhibitor, Oloklignet capsules (brand name: Dongzean, specifications: 20mg, 50mg), received approval from the National Medical Products Administration of China for marketing, aimed at improving blood glucose control in adult patients with type 2 diabetes, either as monotherapy or in combination with metformin [1] - The registration approval was based on two multicenter, randomized, double-blind, placebo-controlled Phase III clinical studies, which showed statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with significant improvements in fasting blood glucose and postprandial blood glucose [1] - The product also demonstrated additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, following cancer and cardiovascular diseases, with the International Diabetes Federation reporting a diabetes prevalence rate of 13.79% among adults (ages 20-79) in China, translating to approximately 148 million patients, the highest in the world [2] - Over 90% of these cases are type 2 diabetes, with a poor medication adherence rate and an effective blood glucose control rate of only 50.1% [2] - The company has a comprehensive product line in the diabetes treatment field, having developed five insulin products that have been approved for marketing, all of which are consistent in efficacy, safety, and quality with original formulations and have been included in the national drug centralized procurement [2] - The approval of the new product will further enrich the company's diabetes product line, leveraging its established production system and marketing network for rapid commercialization, while also exploring clinical applications in diabetes complications to expand the range of indications [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 – 1 – 目前，糖尿病已成為全球範圍內繼腫瘤、心腦血管病之後，第三位嚴重危害人類 健康的慢性非傳染性疾病。國際糖尿病聯盟(IDF)第11版《糖尿病地圖》數據顯示， 中 國 成 人（ 20 – 79 歲 ）糖 尿 病 患 病 率 達 13.79 % ， 患 者 數 量 達 1.48 億 ， 位 居 全 球 首 位 。 其 中 2 型 糖 尿 病 佔 比 超 90 % ， 患 者 臨 床 用 藥 依 從 性 普 遍 不 佳 ， 血 糖 有 效 控 制 率僅有50.1 %。 本集團長期深耕糖尿病治療領域，擁有全面的產品規劃，佈局了完整的產品線。 本集團 ...